Acitretin

Drug Profile

Acitretin

Alternative Names: Acitretine; Etretin; Neotigason; RO 101670; Soriatane

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Allergan; Aralez Pharmaceuticals Inc.; Innovaderm Research; Roche; Stiefel Laboratories
  • Class Antipsoriatics; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • Phase II/III Dermatitis
  • Discontinued Cancer

Most Recent Events

  • 15 Feb 2015 Stiefel Laboratories completes a phase II trial in Psoriasis (Adjunctive treatment) in USA (NCT00156247)
  • 31 Oct 2012 Actavis has been acquired and merged into Watson Pharmaceuticals
  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top